(ARDX) Ardelyx - Ratings and Ratios

Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs, primarily in gastrointestinal and kidney diseases. The company’s lead product, IBSRELA (tenapanor), is a first-in-class, minimally absorbed small molecule therapy approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA works by inhibiting the sodium/hydrogen exchanger NHE3, reducing excessive sodium absorption and improving bowel function. Ardelyx also markets XPHOZAH (tenapanor), a phosphate absorption inhibitor designed to control hyperphosphatemia in adults with chronic kidney disease (CKD) on dialysis, offering a differentiated treatment option with its mechanism of action.

The company, originally founded in 2007 as Nteryx, Inc., rebranded to Ardelyx, Inc. in 2008 and is headquartered in Waltham, Massachusetts. Ardelyx has established a pipeline targeting gastrointestinal and cardiorenal disorders, leveraging its expertise in ion transport mechanisms. Its research and development efforts are focused on addressing significant unmet needs in these therapeutic areas, with an emphasis on improving patient outcomes and quality of life.